Compugen: Preclinical Milestone Met in AstraZeneca Agreement
By Michael Dabaie
Compugen Ltd. said Wednesday its license agreement with
AstraZeneca PLC achieved a preclinical milestone.
Therapeutic discovery and development company Compugen gave an
exclusive license to AstraZeneca for the development of bispecific
and multi-specific antibody products based on one of Compugen's
pipeline programs. AstraZeneca is responsible for all research,
development and commercial activities.
Compugen said that in connection with this first milestone, it
is entitled to receive a $2 million payment from AstraZeneca.
Shares of Compugen were up 4% to $14.76 in premarket
Write to Michael Dabaie at firstname.lastname@example.org
(END) Dow Jones Newswires
December 23, 2020 07:34 ET (12:34 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.